Impact of Active vs Passive Statin Selection for Primary Prevention: The CorCal Vanguard Trial
Authors' conclusion
An active approach to statin selection for primary ASCVD prevention identified a large treatment opportunity and led to over twice as many patients on statins compared to passive (usual care) management.
Study context
- Population
- Patients ≥50 years without history of atherosclerotic cardiovascular disease (ASCVD) or statin use601 consented
- Participants
- 3,770 patients
- Comparison
- Active vs passive statin selection
- Activen = 601
Primary result
As reported in the abstract
Taking a statin · 2.8-year follow-up
P < 0.0001
Further findings
LDL-C · 2.8-year follow-up
P < 0.0001
MACE · 2.8-year follow-up
P = 0.47
Median
| Outcome | Active | Passive | P value |
|---|---|---|---|
| Lipid panels · 2.8-year follow-up | 2.0 | 1.0 | P < 0.0001 |
Statin recommendation among enrolled patients
- Statin recommendation among enrolled patients
- 41.7%
Original publication
Impact of Active vs Passive Statin Selection for Primary Prevention: The CorCal Vanguard Trial. JACC Adv. Published 1 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →